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Swine are an important amplifier of Japanese encephalitis (JE) virus in the paradomestic environment. In this study, two JE
DNA vaccine candidates were evaluated for immunogenicity in swine. Both vaccine plasmids encode a cassette consisting
of the signal of premembrane (prM), prM, and envelope (E) coding regions of JE virus. One plasmid, designated pcJEME, is
based on a commercial vector (pcDNA3), whereas the other plasmid, designated pNJEME, is based on a vector (pNGVL4a)
designed to address some of the safety concerns of DNA vaccine use. No differences were detected in the immunogenicity
of these two plasmids in mice or swine. Swine immunized with the DNA vaccines at a dose of 100 to 450 mg at an interval
of 3 weeks developed neutralizing and hemagglutination-inhibitory (HAI) antibody titers of 1:40 to 1:160 at 1 week after the
second immunization. However, swine administered two doses of a commercial JE vaccine (formalin-inactivated virus
preparation; JEVAX-A) developed low (1:10) or undetectable antibody responses after their boost. Interestingly, serum
antibody titers elicited by DNA vaccines in swine were higher than those detected in mice. Eight days after boosting with viral
antigen (JEVAX-A) to detect an anamnestic response, swine immunized two times with the DNA vaccine showed a .100-fold
elevation in HAI titer, indicating a strong recall of antibody response. Swine maintained detectable levels of HAI antibody for
at least 245 days after two immunizations with a DNA vaccine. These results indicate that these DNA vaccines are able to
induce virus-specific memory B cells and long-lasting antibodies in swine, which were of higher levels than those obtained
with a commercial formalin-inactivated JE vaccine. © 2000 Academic Press
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Japanese encephalitis (JE) virus, which belongs to the
family Flaviviridae, causes infection of the central ner-
vous system in humans and equines and stillbirths in
swine (Shope, 1980; Monath, 1986). The virus has a
zoonotic transmission cycle between birds and mosqui-
toes, with swine serving as an intermediate amplifier
from which anthrophilic mosquitoes become infected,
spreading virus to humans (Scherer et al., 1959; Konno et
al., 1966; Oya, 1967). Therefore, mass vaccination of
swine can prevent disease in swine and help to prevent
JE epidemics in humans (Igarashi, 1992). Current JE vac-
cines for use in swine consist of attenuated or inacti-
vated virus (Fujisaki, 1975; Inoue, 1975; Kurata, 1980a, b;
Yoshida, 1981; Yamagishi, 1989), and there are concerns
about the safety and cost of producing and using these
products. Recently, molecular biology has been used to
develop experimental vaccines for several viral dis-
eases, which could overcome some of the drawbacks of
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49existing vaccines. DNA vaccines are one promising ap-
proach, because they are based on the delivery of inex-
pensive product that encodes only a portion of a viral
genome, enhancing the cost and safety over traditional
vaccines (Manickan et al., 1997).
For the development of second-generation vaccines
against flavivirus diseases, we used a cassette encoding
the signal sequence of premembrane (prM), prM, and
full-length E proteins. Poxviruses that deliver the signal-
prM-E cassette induce expression of subviral extracellu-
lar particles (containing prM/M and E) in cells and elicit
neutralizing antibody and protective immunity in mice
(Mason et al., 1991; Konishi et al., 1991, 1992, 1994). The
se of the signal-prM-E cassette to induce production of
ubviral particles and/or neutralizing antibody in mice
as been reported for a different strain of JE virus (Sato
t al., 1993) and other flaviviruses, such as yellow fever
Pincus et al., 1992), West Nile (Yamshchikov and Com-
ans, 1993), dengue type 1 (Fonseca et al., 1994) and
ick-borne encephalitis (Allison et al., 1995) viruses. In
ddition to their immunogenicity in mice, poxviruses en-
oding the JE virus signal-prM-E gene cassette have
een reported to elicit neutralizing antibody in swine and
umans (Konishi et al., 1992, 1998a). Furthermore, we
ave demonstrated that memory cytotoxic T lymphocytes
CTLs), another important arm of immunity, are induced
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50 KONISHI ET AL.in mice and humans by this gene cassette (Konishi et al.,
997, 1998a). We developed a pcDNA3-based DNA vac-
ine containing the signal-prM-E gene cassette of JE
irus (designated pcJEME here; it is identical to
cDNA3JEME reported in Konishi et al., 1998b), and dem-
nstrated an ability of pcJEME to induce neutralizing
ntibody, memory CTLs, and protective immunity in mice
Konishi et al., 1998b). The induction of protective immu-
nity against flaviviruses by other DNA vaccines has been
reported using the nonstructural (NS) 1 gene of JE virus
(Lin et al., 1998), the signal, prM and truncated E genes
of dengue type 2 virus (Kochel et al., 1997; Porter et al.,
1998), and the signal, prM, and full-length E genes of St.
Louis (Phillpotts et al., 1996) and tick-borne (Schmaljohn
et al., 1997) encephalitis viruses.
Although pcJEME displayed promising properties in
murine studies, the vector used to construct this vaccine
candidate contains an ampicillin-resistance gene and
sequences derived from SV40 virus. The former element
is thought to be undesirable because it could be incor-
porated into pathogenic bacteria in inoculated animals,
rendering them resistant to useful antibiotics, whereas
the latter element is thought to be potentially dangerous
because SV40 is an oncogenic virus that transforms
human cells in tissue culture (Noonan and Butel, 1978).
Therefore, we selected an alternative vector, pNGVL4a,
which uses a kanamycin-resistance gene and does not
contain any SV40-derived sequences (Hartikka et al.,
1996; Doolan et al., 1997), to construct a new prM/E-
encoding DNA vaccine candidate, pNJEME.
The purpose of the present study was to evaluate
immunogenicity of pcJEME and pNJEME in swine. Both
of the JE DNA vaccine candidates induced neutralizing
and hemagglutination-inhibiting (HAI) antibodies in swine
at levels greater than those detected in inactivated vac-
cine-vaccinated animals. Furthermore, DNA-vaccinated
swine showed a brisk recall immune response and long-
lived antibody.
RESULTS
In vitro expression of vaccine plasmids
pcJEME and pNJEME specify the expression of prM
and E in vitro. CHO-K1 cells transfected with 0.5 mg of
cJEME or pNJEME were immunostained with monoclo-
al antibodies to prM (J2-2F1; provided by Dr. Mary K.
entry of Walter Reed Army Institute of Research, Wash-
ngton, DC) or E (J3-11B9; Mason et al., 1989) to deter-
mine the levels of viral antigens specified by these plas-
mids. Interestingly, these studies failed to detect any
difference in the levels of antigen produced by these two
plasmids, even though pNJEME contains an intron,
which was expected to improve its ability to produce
antigen-encoding mRNA.Immunogenicity of pNJEME in mice
Mice immunized with pNJEME developed a neutraliz-
ing antibody titer of 1:10 at 2 weeks after the second
immunization. In controls, mice immunized with pcJEME
or a commercial JE vaccine for human use (JEVAX-H)
developed an equivalent titer (1:10), whereas no detect-
able neutralizing antibody was obtained in mice immu-
nized with pNGVL4a. After challenge with a lethal dose
of the P3 strain of JE virus, five of six mice immunized
with pNJEME survived for 21 days. The same survival
rate was obtained with mice immunized with pcJEME or
the JEVAX-H, whereas all mice inoculated with pNGVL4a
died of challenge. These results indicate that immuniza-
tion with pNJEME induces neutralizing antibody and pro-
tective immunity in mice. The induction of neutralizing
antibody and protective immunity by pcJEME has been
reported previously (Konishi et al., 1998b).
Induction of neutralizing and HAI antibodies in swine
Five groups of five pigs were inoculated twice with
pNJEME, pcJEME, or a commercial JE vaccine for animal
use (JEVAX-A) and bled every week until week 12 after
the first inoculation. Serum levels of neutralizing and HAI
antibody titers were assessed until weeks 8 and 12,
respectively. The time courses of neutralizing and HAI
antibodies in pooled sera are shown in Fig. 1, and the
distributions of individual antibody titers on weeks 4 and
FIG. 1. Time course of neutralizing (top) and HAI (bottom) antibody
titers determined for sera pooled from each group of five immunized
pigs. (Left) Pigs were immunized i.m. or i.d. with pcJEME at a dose of
450 or 100 mg. (Right) Pigs were immunized i.m. with pNJEME at a dose
of 450 mg or s.c. with JEVAX-A at the single dose recommended by the
manufacturer. Immunizations were performed at weeks 0 and 3 for
pcJEME and pNJEME (arrows) and at weeks 0 and 2 for JEVAX-A
(arrowheads). Pigs were bled 16 days before the first immunization
(week 0) and every week until week 12. Neutralization titers were
obtained with sera collected until week 8.7 are shown in Fig. 2. Variations of individual antibody
titers were 2- to 8-fold among each group and were
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51IMMUNOGENICITY OF JE DNA VACCINE IN SWINEobserved for both neutralizing and HAI antibodies (Fig.
2). No systemic or local reactions were observed in any
swine after intramuscular (i.m.) or intradermal (i.d.) inoc-
ulation with plasmid DNAs. As expected from earlier
studies (Konishi et al., 1992), HAI and neutralizing anti-
body titers were directly related to each other for each
individual animal and for each group of swine.
Swine immunized by i.m. inoculation with 450 mg of
pcJEME developed a neutralization titer of 1:10 at 2
weeks after the first immunization and a titer of 1:80 at 1
week after the second immunization (Fig. 1). The neu-
tralization titer was maintained at 1:80 for 2 weeks and
then gradually declined. In the 100-mg inoculation group,
detectable levels of neutralizing antibodies were not ob-
served before the second immunization, with a neutral-
ization titer of 1:40 detected 1 week after the second
immunization. As expected (see earlier), the time course
of HAI antibody titers (Fig. 1) and individual antibody
titers on weeks 4 and 7 (Fig. 2) showed the same rela-
tionship. Taken together, these results indicate that
pcJEME is able to induce neutralizing and HAI antibodies
in all swine vaccinated with two doses of 100 and 450 mg
and that the higher dose elicited higher titers of antibod-
ies in both tests.
Examination of the immunogenicity of 450 mg of
pcJEME by the i.d. route revealed a similar time course of
antibody production (Fig. 1) and a consistent immune
response among vaccinated animals (Fig. 2). However,
the i.d. route elicited lower levels of antibodies (as mea-
sured by both neutralization and HAI assays) than i.m.
inoculation (Figs. 1 and 2).
Swine inoculated i.m. with 450 mg of pNJEME devel-
ped neutralizing and HAI antibodies in a manner indis-
inguishable from swine inoculated i.m. with 450 mg of
FIG. 2. Neutralizing (left) and HAI (right) antibody titers observed in
sera from individual pigs on week 4 (top) and week 7 (bottom) after the
first immunization. Groups of five pigs were immunized i.m. or i.d. with
450 or 100 mg of pcJEME, i.m. with 450 mg of pNJEME, or s.c. with one
dose of JEVAX-A (see legend to Fig. 1 for details).pcJEME (Figs. 1 and 2). Thus, with these criteria for
immunogenicity, pNJEME was as effective as the ampi-
o
dcillin-resistance gene- and SV40 DNA-containing
pcJEME plasmid as a DNA vaccine candidate.
Swine vaccinated twice with JEVAX-A developed HAI
antibody titers at a maximum of 1:10 within the 12-week
experimental period, but no detectable levels of neutral-
izing antibodies were observed in pooled sera for 8
weeks after the first immunization (Fig. 1). These results
indicate that our DNA vaccines induce stronger immune
responses in swine than a currently approved JE vac-
cine.
Anamnestic HAI antibody responses in pNJEME-
immunized swine
To examine an ability of pNJEME to induce memory B
and helper T cells, the swine immunized twice with
pNJEME or JEVAX-A were boosted with JEVAX-A (three
pigs from each group) or mock-boosted with saline (re-
maining two pigs in each group) and examined for the
anamnestic responses with the HAI antibody test (Fig. 3).
All three of the pNJEME-immunized pigs that were
boosted had an HAI titer of 1:20 before boosting. After
boosting, these swine developed HAI titers from 1:20 to
1:40 on day 2, from 1:40 to 1:80 on day 4, and 1:2560 on
day 8 (Fig. 3). The three JEVAX-A-immunized pigs had
HAI titers from ,1:10 to 1:10 before boosting and from
1:10 to 1:80 on day 8. Mock-boosted swine had the same
HAI titers on days 0 and 8 in both groups. Thus pNJEME-
immunized swine produced a significantly stronger
anamnestic antibody response than swine immunized
with JEVAX-A, suggesting that pNJEME induces more
memory B and helper T cells than the currently used
commercial vaccine.
Duration of immunity induced by pNJEME in swine
Sera were periodically collected from two pigs immu-
nized twice with pNJEME and two pigs immunized twice
FIG. 3. Anamnestic HAI antibody responses to viral antigen in swine
immunized twice with 450 mg of pNJEME (left) or twice with the
anufacturer’s recommended dose of JEVAX-A (right). Three of five
igs in each group were boosted s.c. with 2 ml of JEVAX-A on day 116.
s a control, the remaining two pigs were mock-boosted s.c. with 2 ml
f saline. Sera were collected before boosting (day 0) and 2, 4, and 8
ays after boosting and examined in the HAI test.
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52 KONISHI ET AL.with JEVAX-A until the end of the experimental period
(day 245 after the first immunization) and were examined
for HAI antibody levels (Table 1). The swine immunized
with pNJEME showed detectable levels of HAI antibody
from day 84 to day 245, and the HAI titers tended to
increase with increasing period after the immunization.
In contrast, no detectable levels of HAI antibodies were
obtained in two pigs immunized with JEVAX-A in this
period. This result indicates that immunization with pN-
JEME induces long-lasting antibody responses in swine.
DISCUSSION
Several devices to increase the levels of expression
and/or immunogenicity of JE viral proteins were incorpo-
rated into pcJEME and pNJEME. Both vaccine candi-
dates contain a strong eukaryotic promoter derived from
human cytomegalovirus, a polyadenylation signal, a
strong eukaryotic initiation site (an ACC sequence pre-
ceding the AUG start codon; Kozak, 1986), and the im-
munostimulatory sequences on the native (pcJEME) or
modified (pNJEME) ampicillin-resistance gene (Sato et
al., 1996). In addition to these devices, pNJEME con-
tained an intron A sequence downstream of the cyto-
megalovirus promoter and upstream of the eukaryotic
initiation site. An addition of the intron A sequence has
been reported to increase the level of gene expression
(Chapman et al., 1991). In the present study, however,
cJEME and pNJEME induced similar levels of both ex-
ression in vitro and immunogenicity in mice and swine.
xplanations for the failure of the intron A to increase
TABLE 1
Duration of Immunity Induced by pNJEME in Swine
Day after the first
immunizationb
HAI titer
JEVAX-Aa pNJEME
No. 107c No. 108 No. 127 No. 128
84 ,1:10 ,1:10 1:10 1:20
98 ,1:10 ,1:10 1:10 1:20
116 ,1:10 ,1:10 1:10 1:20
124 ,1:10 ,1:10 1:10 1:20
154 ,1:10 ,1:10 1:10 1:40
195 ,1:10 ,1:10 1:20 1:80
217 ,1:10 ,1:10 1:20 1:80
245 ,1:10 ,1:10 1:20 1:40
a Inactivated vaccine for animal use.
b Pigs were inoculated with one dose of JEVAX-A twice on days 0 and
14 or with 450 mg of pNJEME on days 0 and 21. All four pigs shown were
injected with saline on day 116 as a mock-boosted control in the
experiment to detect anamnestic responses (see Materials and Meth-
ods for details).
c Animal number.evels of expression include the possibility that mRNA
rocessing is not the rate-limiting step in synthesis of therotein (which may include the assembly and release of
he extracellular prM/E-containing particles). Alterna-
ively, the products of the JE gene cassette could display
ome toxic properties, which could be exacerbated by
nhanced synthesis.
Swine showed relatively high levels of antibody re-
ponses to DNA plasmids, although two immunizations
ere carried out on contralateral sides, which may result
n weaker immune responses than ipsilateral inocula-
ions. Furthermore, the DNA plasmids induced higher
ntibody levels in swine than in mice, which developed
nly low or undetectable levels of antibody as deter-
ined by the same serological methods in this and
revious studies (Konishi et al., 1998b). Specifically, two
.m. inoculations with 100 mg of pcJEME provided 4-fold
igher neutralizing antibody titers in swine (1:80) than in
ice (1:20 in sera pooled from five animals 2 weeks after
he second immunization). This was in contrast to our
revious data showing that the same JE virus prM/E
ene cassette vectored by a vaccinia virus induced
eaker humoral immune responses in swine than in
ice (Konishi et al., 1992). We did not investigate CTL
esponses in this study due to the difficulty of performing
he assays on outbred animals and because our previ-
us study indicated that CTLs induced by pcJEME are
ess important than neutralizing antibody in protecting
ice from JE (Konishi et al., 1999).
As an alternative to the live-virus challenge experi-
ent, we boosted immunized swine with a viral antigen
nd examined anamnestic antibody responses to evalu-
te the potential protective capacity of pNJEME in swine.
e previously demonstrated that low levels of neutraliz-
ng antibodies are able to protect swine from viremia and
hat strong anamnestic responses are elicited on chal-
enge of swine (Konishi et al., 1992). Furthermore, our
revious study of postchallenge antibody responses in
ice immunized with pcJEME demonstrated that neutral-
zing antibody produced after challenge is the critical
omponent for protection of mice from lethal infection
Konishi et al., 1999). Immunized mice that showed the
significant elevation of neutralization titers on day 4 after
challenge were protected, whereas none of the unimmu-
nized mice showed any significant elevation and were
not protected (Konishi et al., 1999). The presence of
memory B and helper T cells in mice inoculated with
pcJEME appears to be important in postchallenge anti-
body responses and subsequent protection. In the
present study, a rapid elevation of HAI antibody titers
after boosting with JEVAX-A was observed in all three
pigs immunized with pNJEME. Because the timing of
elevation coincides well with the period of viremia in
swine experimentally infected with JE virus (Kodama et
al., 1968; Fujisaki et al., 1975; Sasaki et al., 1982; Konishi
et al., 1992) and because HAI antibody titers correlated
with neutralizing antibody titers in swine (Figs. 1 and 2),
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53IMMUNOGENICITY OF JE DNA VACCINE IN SWINEit appears likely that two immunizations with pNJEME
would prevent viremia in swine.
The commercially available inactivated JE vaccine
JEVAX-A did not elicit high levels of antibodies in swine
in the present study, although the immunization protocol
was in accord with the instructions supplied by the
manufacturer. However, the immunogenicity of JEVAX-A
was demonstrated, because swine immunized with pN-
JEME developed extremely high levels of antibody re-
sponses after boosting with JEVAX-A. Two immunizations
plus one-boost immunization with JEVAX-A, for a total of
three inoculations, induced a modest level of antibody
response. In conclusion, pcJEME and pNJEME induced
higher levels of antibody responses than the commercial
inactivated JE vaccine in swine. Also, the levels of anti-
body responses induced by these DNA vaccine plasmids
were comparable or higher than those induced in swine
by a recombinant vaccinia virus encoding the JE virus
signal-prM-E gene cassette (vP923; Konishi et al., 1992).
Thus, pNJEME appears to be a promising JE DNA vac-
cine candidate for the prevention of viremia in swine and
control of the transmission of JE virus infection to hu-
mans.
MATERIALS AND METHODS
Plasmids
The construction of pcJEME, which is a pcDNA3-
based plasmid encoding the JE virus (Nakayama strain)
signal sequence of prM, prM, and E genes, has been
described previously (Konishi et al., 1998b). The
pNGVL4a vector, which possesses an eukaryotic pro-
moter derived from human cytomegalovirus with the
intron A sequence, a polyadenylation signal, and an
immunostimulatory sequence on the modified ampicillin-
resistance gene (Sato et al., 1996), and lacking SV40-
derived sequences, was supplied by the National Gene
Vector Laboratory (University of Michigan). For construc-
tion of pNJEME, the JE virus signal-prM-E gene cassette
was cloned from pcJEME into the pNGVL4a vector and
resequenced. All plasmid DNAs (pcJEME, pcDNA3, pN-
JEME, pNGVL4a) were purified using a Qiagen Plasmid
Kit (Funakoshi Co. Ltd., Tokyo, Japan).
Inactivated vaccines
The formalin-inactivated, mouse brain-derived JE vac-
cines for human use (JEVAX-H; Institute for Microbial
Diseases of Osaka University, Kagawa, Japan) and for
animal use (JEVAX-A; Institute of Chemical and Serum
Therapy, Kumamoto, Japan) were selected in this study,
because the Nakayama strain is used to prepare these
vaccines.
Experiments in miceFour groups of six 6-week-old male BALB/c mice were
inoculated i.m. with 100 mg of pNJEME, pcJEME, orNGVL4a or intraperitoneally (i.p.) with 1/10 dose of
EVAX-H twice at an interval of 2 weeks (at 6 and 8 weeks
f age). Two weeks after the second immunization (at 10
eeks of age), these mice were bled retroorbitally for
erological evaluation. One week after the bleeding (at
1 weeks of age), the six mice were challenged by i.p.
njection with a dose of 50,000 LD50 of the Beijing P3
strain of JE virus (Mason et al., 1991) and observed for 3
weeks.
Experiments in swine
Five groups of five 8- to 12-week-old pigs with a body
weight of 13–14 kg (castrated males and females of the
Yorkshire breed) were inoculated with 100 or 450 mg of
pcJEME or 450 mg of pNJEME twice on days 0 and 21 or
with the recommended dose of JEVAX-A on days 0 and
14. The plasmid DNAs diluted in PBS were injected i.m.
at a single site on the neck (in the trapezius muscle) with
a volume of 1 ml or i.d. at two sites on the base of the ear
with a volume of 200 ml for each site. The JEVAX-A was
inoculated subcutaneously (s.c.) with a volume of 1 ml on
the neck. For injection of all immunogens, the right side
of each animal was used for the first immunization and
the left side was used for the second immunization.
Swine were bled 16 days before the first immunization
and every week for 12 weeks after the first immunization.
Serum samples were isolated from blood, pooled, and
examined for neutralizing and/or HAI antibodies. Individ-
ual sera collected on weeks 4 and 7 were also tested. All
swine were monitored for adverse clinical manifesta-
tions due to vaccination. Anamnestic antibody re-
sponses were examined by boosting with a viral antigen
on day 116 using two groups of five pigs immunized with
pNJEME or JEVAX-A. Three of five pigs in each group
were boosted by s.c. inoculation with 2 ml of JEVAX-A,
and the remaining two for each group were mock-
boosted s.c. with 2 ml of saline. Three boosted pigs were
bled on day 116 (just before boosting) and on days 2, 4,
and 8 after boosting (days 118, 120, and 124). Two mock-
boosted pigs were bled on days 116 and 124. Sera from
all of these samples were tested individually for HAI
antibody. To examine the duration of antibody, sera were
monitored periodically from the two pigs from each of
pNJEME- or JEVAX-A-immunization groups, which were
mock boosted with saline on day 116.
Serological tests
Neutralizing antibodies elicited in immunized mice or
swine were determined using the Nakayama strain of JE
virus as previously described (Konishi et al., 1999). The
neutralization titer was expressed as the greatest serum
dilution yielding a 90% reduction in plaque number. The
HAI test was performed as previously described (Mason
et al., 1991), except for the use of a commercial JE virus
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54 KONISHI ET AL.antigen for diagnostic use (Takeda Pharmaceutical Co.,
Osaka, Japan).
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